Pfizer (PFE) Revenue — Quarter Ended Jun 29, 2025
In the latest quarter, Pfizer's revenue increased compared to both the immediately preceding quarter and the same quarter one year earlier. The company continues to focus on business development and pipeline advancement.
Key takeaway
Quarter ended Jun 29, 2025 · FY2025 Q2
In the latest quarter, Pfizer's revenue increased compared to both the immediately preceding quarter and the same quarter one year earlier. The company continues to focus on business development and pipeline advancement.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$14.7B
Revenue reported for this quarter.
Quarter-over-quarter
+6.8%
Change from the immediately preceding quarter.
Year-over-year
+10.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$63.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 29, 2024 | $17.7B | +31.2% |
| Dec 31, 2024 | $17.8B | +21.9% |
| Mar 30, 2025 | $13.7B | -7.8% |
| Jun 29, 2025 | $14.7B | +10.3% |
Revenue performance
Revenue showed positive growth from the prior quarter, reversing a decline in the earlier part of the fiscal year. Year-over-year, revenue also rose, indicating stronger performance than the same period last year.
Quarterly comparison
Compared to the first quarter of this fiscal year, revenue posted a solid increase. Against the comparable quarter in the prior year, revenue was also higher, reflecting a sustained improvement.
What to watch
Watch for developments related to the company's recent strategic transactions, including the in-licensing agreement announced after the quarter end.